INEGY 10 MG80 MG TABLETS

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

EZETIMIBE; SIMVASTATIN

Disponible desde:

MERCK SHARP & DOHME ISRAEL LTD

Código ATC:

C10AA01

formulario farmacéutico:

TABLETS

Composición:

SIMVASTATIN 80 MG; EZETIMIBE 10 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricado por:

MERCK SHARP & DOHME B.V., THE NETHERLANDS

Grupo terapéutico:

SIMVASTATIN

Área terapéutica:

SIMVASTATIN

indicaciones terapéuticas:

Hypercholesterolemia: Inegy is indicated as adjunctive therapy to diet for use in patients with primary ( heterozygous familial and nonfamilial) hypercholesterolemia or mixed hyperlipidemia where use of a combination product is appropriate: - patients not appropriately controlled with a statin alone - patients already treated with a statin and ezetimibe. Inegy contains ezetimibe and simvastatin. Simvastatin ( 20 - 40 mg ) has been shown to reduce the frequency of cardiovascular events. Studies to demonstrate the efficacy of inegy or ezetimibe in the prevention of complications of atherosclerosis have not been completed. Homozygous familial hypercholesterolemia (HoFH): Inegy is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments ( e.g. low-density lipoprotein [LDL] apheresis).

Fecha de autorización:

2012-04-30